ALK-abello A/S Class B ( (AKBLF) ) has released its Q2 earnings. Here is a breakdown of the information ALK-abello A/S Class B presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ALK-Abelló A/S, a Danish pharmaceutical company specializing in allergy immunotherapy, has reported a robust financial performance for the second quarter of 2025, marked by a 12% organic revenue growth and a 41% increase in operating profit. The company’s performance was bolstered by strong sales of tablets and adrenaline autoinjectors, particularly in Europe and North America, despite challenges in international markets. Key highlights include a 16% growth in tablet sales and a 56% increase in anaphylaxis revenue, driven by the Jext® product line. The company’s EBIT margin improved to 25%, supported by sales growth and optimization initiatives. Looking ahead, ALK-Abelló has upgraded its full-year revenue outlook to 12-14% growth, driven by increased patient treatment with its allergy and anaphylaxis products, and anticipates further improvements in its EBIT margin.